Business Context and Reporting Period
This Form 8-K was filed by Lipocine Inc. on April 21, 2020. The report addresses a regulatory event concerning the company's compliance with The Nasdaq Stock Market listing requirements, specifically regarding the minimum bid price of its common stock.
Key Financial Metrics
This filing is a Current Report regarding a corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Events
- Nasdaq Non-Compliance: Lipocine previously received notice that it failed to meet Nasdaq Listing Rule 5450(a)(1) because its stock closed below $1.00 per share for 30 consecutive business days.
- Compliance Tolling: On April 17, 2020, Nasdaq granted a tolling period due to extraordinary market conditions, extending the compliance deadline through June 30, 2020.
- New Deadline: Upon expiration of the tolling period, Lipocine has 69 calendar days (from July 1, 2020, to September 7, 2020) to regain compliance.
Outlook, Risks, and Contingencies
Compliance Requirement: To regain compliance, the closing bid price of Lipocine's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days. This must occur either during the tolling period or within the 69-day window following it.
Extension Possibility: The Nasdaq Staff retains discretion to extend the 10-business-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(F).
Risk: Failure to meet the bid price requirement by the final deadline could result in delisting from The Nasdaq Stock Market.
Investor Verification Checklist
- Verify the current trading price of Lipocine (LPCN) to assess proximity to the $1.00 threshold.
- Monitor the stock's closing prices daily to track progress toward the 10 consecutive business days requirement.
- Review subsequent filings for any announcements regarding a reverse stock split or other capital structure changes intended to address the bid price deficiency.
- Check for any further communications from Nasdaq regarding extensions or rule changes affecting the compliance timeline.